{"DataElement":{"publicId":"4750626","version":"1","preferredName":"Patient Immunosuppressive Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has meets the eligibility criteria for immunosuppressive therapy.","longName":"IMMUNO_TX_CTEC_C_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"3536195","version":"1","preferredName":"Patient Immunosuppressive Therapy Clinical Trial Eligibility Criteria","preferredDefinition":"information relating to patient eligibility criteria and immunosuppressive therapy (therapy used to decrease the body's immune response, such as drugs given to prevent transplant rejection) as elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"2233604v1.0:3536193v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3536193","version":"1","preferredName":"Immunosuppressive Therapy Clinical Trial Eligibility Criteria","preferredDefinition":"deliberate suppression of immune system function for experimental or therapeutic purposes.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C15261:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunosuppressive Therapy","conceptCode":"C15261","definition":"deliberate suppression of immune system function for experimental or therapeutic purposes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5C0D4AE-1899-2CC8-E040-BB89AD433375","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"LEL","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5C0D4AE-18AA-2CC8-E040-BB89AD433375","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"LEL","dateCreated":"2012-07-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"10000083","version":"1","longName":"Physical & Concomitant Requirements","context":"Theradex"},{"publicId":"3876424","version":"1","longName":"Prior Treatments","context":"Theradex"}]}],"AlternateNames":[{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"IMMUNO_TX_CD_IND","type":"OID, Theradex","context":"Theradex"}],"ReferenceDocuments":[{"name":"Theradex - 1","type":"Alternate Question Text","description":"Patient does not require immunosuppressive doses of systemic corticosteroids (greater than 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration?","url":null,"context":"Theradex"},{"name":"Does patient have a condition","type":"Preferred Question Text","description":"Does patient have a condition requiring systemic treatment with either corticosteroids (greater than 10 mg daily prednisone equivalents) or other immunosuppressive medications within 7 days of study drug administration?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Does patient require active systemic immunosuppressive therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Does patient have any condition requiring greater than 10 mg/d prednisone equivalents?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Does patient require daily corticosteroids at high doses (prednisone greater than or equal 20 mg daily, or an equivalent) from 28 days prior to first dose and during treatment with ibrutinib?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Does patient with autoimmune disease requiring systemic corticosteroid treatment (and previously ineligible to receive systemic immunotherapies for melanoma) not require more than 20mg of daily dose methylprednisone or its equivalent?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"If patient has received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) was last dose a minimum of 2 weeks prior to Cycle 1, Day 1? ","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Is patient on systemic corticosteroids (IV or oral steroids, excluding inhaled, topical or ophthalmic corticosteroids), or anti-epileptic drugs for treated brain metastasis, or strong CYP3A4/CYP2C19 inducers/inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Has patient received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Has patient been off systemic immunosuppressive medications greater than 2 weeks prior to treatment start?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Has patient received treatment immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1? \r\n","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Is patient on systemic corticosteroids (IV or oral steroids, excluding inhaled, topical or ophthalmic corticosteroids), or anti-epileptic drugs for treated brain metastasis?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Does patient require the use of corticosteroids to control cerebral edema or treat neurologic symptoms?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Is patient receiving or has received systemic immunosuppressive therapy (greater than  2 weeks) including oral steroid doses greater than 10 mg/day of prednisone or equivalent within 2 months prior to enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Has patient been diagnosed with immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Was last dose of systemic corticosteroid greater than 10mg/day of Prednisone or equivalent greater than or equal to 4 weeks?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Does patient require daily corticosteroids at high doses (prednisone greater than or equal to 20 mg daily, or an equivalent) from 28 days prior to first dose and during treatment with ibrutinib?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Has patient received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 6 weeks prior to Cycle 1, Day 1?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Does patient with autoimmune disease requiring systemic corticosteroid treatment (and previously ineligible to receive systemic immunotherapies for melanoma) not require more than 20mg of daily dose methylprednisone, prednisone, or its equivalent?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Is patient receiving systemic glucocorticoids for any purpose other than to modulate symptoms from an event of suspected immunologic etiology?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Has patient received systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Has patient received treatment with systemic immunosuppressive medications (including, but not limited to, oral prednisone (greater than 10 mg/day or equivalent), cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to initiation of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Has patient received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to start of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Does patient require the use of anti-tumor necrosis factor (anti TNF) therapies, such as infliximab, or patients who have received treatment with anti-TNF therapies within 5 half-lives of the drug (48 days for infliximab, 55 days for golimumab, 70 days for certolizumab and adalimumab, and 16 days for etanercept)?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"If patient is on corticosteroids for the treatment of brain metastases, is the dose less than or equal to 10 mg of prednisone-equivalent and has not been increased within 2 weeks (14 days) of screening and patient is asymptomatic?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"Is patient currently receiving or received systemic immunosuppressive medication (except corticosteroids at physiological doses, not exceeding 10 mg prednisone-equivalent day) within 10 days before the first dose of study medication?","url":null,"context":"Theradex"},{"name":"NRG_CRF_Text 1","type":"Alternate Question Text","description":"Does patient have a condition requiring systemic treatment with either corticosteroids (greater than 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration? (Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease)","url":null,"context":"NRG"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Does patient require continued treatment with systemic immunosuppressive agents?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Does patient require systemic corticosteroids treatment (greater than or equal to 10 mg/day prednisone equivalents) or other immunosuppressive medications within 14 days prior to study drug administration?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"Is patient receiving, or has received during the 14 days prior to first dose, corticosteroids at a dose of greater than 10 mg prednisone/day or equivalent for any reason?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Is patient receiving immunosuppressive therapy (except for corticosteroid doses as noted in section 3.2.8)?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Is patient receiving systemic corticosteroid therapy at a daily dose higher than 15 mg prednisone or equivalent and previous corticosteroid therapy has not been stopped or reduced to the allowed dose at least 7 days prior to the CT/MRI screening?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Has patient received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 6 weeks prior to start of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Does patient require immunosuppressive therapy while on study?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Does patient require systemic corticosteroids treatment (greater than or equal to 10 mg/day prednisone equivalents) or other immunosuppressive medications within 28 days prior to study drug administration?","url":null,"context":"Theradex"},{"name":"NRG_CRF_Text_2","type":"Alternate Question Text","description":"Is patient on dose of steroids <10 mg prednisone a day or equivalent?","url":null,"context":"NRG"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Is patient currently receiving or has received immunosuppressive medication within 14 days before the first dose of MEDI4736 (durvalumab) or tremelimumab, with the exceptions of intranasal, inhaled, topical steroids or local steroid injections (e.g. intra-articular injection), systemic corticosteroids at physiological doses which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroid and steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication)?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Is patient currently receiving or has received immunosuppressive medication within 14 days before the first dose of MEDI4736 (durvalumab) or tremelimumab, with the exceptions of intranasal, inhaled, topical steroids or local steroid injections (e.g. intra-articular injection), systemic corticosteroids at physiological doses which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroid and steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication?","url":null,"context":"Theradex"},{"name":"NRG CRF_Text 3","type":"Alternate Question Text","description":"Does the patient have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalents) or other immunosuppressive medications within 14 days of registration?","url":null,"context":"NRG"},{"name":"NRG CRF_Text4","type":"Alternate Question Text","description":"Does the patient have a chronic medical condition requiring a higher dose of corticosteroids (prednisone/prednisolone) than 10 mg daily","url":null,"context":"NRG"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Has patient received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone [greater than 10 mg/day], cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"Has patient received systemic corticosteroids or other forms of immunosuppressive therapy within 7 days prior to initiation of protocol therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"Does patient require ongoing use of systemic corticosteroids or immunosuppressive agents within 14 days?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"Has patient received corticosteroids (at a dose greater than 10 mg prednisone/day or equivalent) for any reason within 2 weeks prior to first dose?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Is patient currently using corticosteroids, except for low doses of steroids (less than 10 mg of prednisone or equivalent dose of other steroid) used for treatment of non-hematologic medical condition (e.g., chronic adrenal insufficiency)?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Does patient require systemic corticosteroid or other immunosuppressive therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"Has patient received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and antitumor necrosis factor [anti-TNF] agents) within 2 weeks before initiation of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"If patient has prior treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-a or interleukin [IL]-2), was last dose a minimum of 4 weeks or 5 half-lives of the drug (whichever is longer) prior to Cycle 1, Day 1?","url":null,"context":"Theradex"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Did the patient require steroids for prior immune related colitis?","url":null,"context":"NRG"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"Has patient received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1 or anticipation of need for systemic immunosuppressive medication during study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 46","type":"Alternate Question Text","description":"Does the patient have undiagnosed immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment?","url":null,"context":"Theradex"},{"name":"NRG CRF_Text 5","type":"Alternate Question Text","description":"Does the patient require chronic corticosteroid therapy of greater than 10mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressant agents for a chronic disease?","url":null,"context":"NRG"},{"name":"NRG_CRF_Text_6","type":"Alternate Question Text","description":"Is patient on dose of steroids  greater than 10 mg prednisone a day or equivalent?","url":null,"context":"NRG"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"Is patient receiving treatment with systemic immunosuppressive medications (including, but not limited to, prednisone [greater than 10 mg/day], cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"Does patient require immunosuppressive treatments for comorbidities?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"If patient requires inhaled or topical steroids or adrenal replacement doses greater than 10 mg daily prednisone equivalents, patient does not have active autoimmune disease?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"Has patient received systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to first dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 51","type":"Alternate Question Text","description":"Is patient on chronic corticosteroid treatment, beyond physiological replacement?","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11F97955-EA10-7C12-E050-BB89AD436DE4","latestVersionIndicator":"Yes","beginDate":"2015-03-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-23","modifiedBy":"SOKKERL","dateModified":"2023-08-28","changeDescription":"12/5/16 tt, added CSI. 9672_Theradex_03.23.15_ghd","administrativeNotes":"2022.11.18 AQT added for NRG ticket request CADSR0001716 cjl; 2022.11.15 AQT added for ticket request CADSR0001687. ak","unresolvedIssues":null,"deletedIndicator":"No"}}